Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167934 · ClinicalTrials.gov registry record · NA
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
A NA study of Schizophrenia, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 164
- Enrollment target
- 1
- Study location
NCT00167934: Completed NA study of Schizophrenia, sponsored by Washington University School of Medicine.
NCT00167934 is a NA study of Schizophrenia that has completed, run by Washington University School of Medicine. The registered enrollment target is 164 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00167934, a NA study of Schizophrenia, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 164 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate.
Primary Outcome
Change in body composition (total body fat) was assessed using dual energy x-ray absorptiometry
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valproate
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00167934 record still lists
NCT00167934 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00167934 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00167934 about?
NCT00167934 is a clinical study titled "Determining Metabolic Effects of Valproate and Antipsychotic Therapy". This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate.
What is the current status of trial NCT00167934?
This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2004-12. Estimated completion is 2008-12.
What conditions does trial NCT00167934 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00167934?
The interventions under investigation include: Placebo (DRUG), Valproate (DRUG).
Who is sponsoring clinical trial NCT00167934?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00167934 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00167934's enrollment target sits among peer trials
164 99th of 315 higher than 215 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia